EYEG - Eyegate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5901
-0.0481 (-7.5368%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.6382
Open0.6600
Bid0.6500 x 1000
Ask0.7180 x 100
Day's Range0.5801 - 0.6600
52 Week Range0.4950 - 3.9000
Volume164,510
Avg. Volume422,560
Market Cap10.153M
Beta2.83
PE Ratio (TTM)N/A
EPS (TTM)-1.1350
Earnings DateFeb 21, 2018 - Feb 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    EyeGate to Present at the 2018 BIO CEO & Investor Conference

    WALTHAM, Mass., Feb. 07, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, ...

  • SmarterAnalyst16 days ago

    What Spooked Eyegate Pharmaceuticals Inc Investors Today

    Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) dropped by as much as 47% in early trading Monday. The reason? The stock's double-digit nosedive was sparked by disappointing top-line results from a phase 2b trial of the company's EGP-437 combination product for pain and inflammation in patients having undergone cataract surgery.

  • GlobeNewswire16 days ago

    EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

    WALTHAM, Mass., Feb. 05, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, ...

  • Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?
    Simply Wall St.last month

    Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?

    Stephen From is the CEO of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG), which has recently grown to a market capitalization of $20.65M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...

  • GlobeNewswire2 months ago

    EyeGate Promotes Sarah Romano to Chief Financial Officer

    WALTHAM, Mass., Jan. 04, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, today announced ...

  • With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?
    Simply Wall St.2 months ago

    With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?

    Understanding how Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...

  • Capital Cube2 months ago

    ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EyeGate Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EYEG-US. Comparing the performance and risk of EyeGate Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • GlobeNewswire2 months ago

    EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye

    WALTHAM, Mass., Dec. 19, 2017-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, today announced ...

  • GlobeNewswire2 months ago

    EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment

    WALTHAM, Mass., Dec. 18, 2017-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, reported ...

  • Capital Cube3 months ago

    ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EyeGate Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EYEG-US. Comparing the performance and risk of EyeGate Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • What Does Eyegate Pharmaceuticals Inc’s (EYEG) Share Price Indicate?
    Simply Wall St.3 months ago

    What Does Eyegate Pharmaceuticals Inc’s (EYEG) Share Price Indicate?

    Eyegate Pharmaceuticals Inc (NASDAQ:EYEG), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. LessRead More...

  • Zacks Small Cap Research3 months ago

    EYEG: Cataract Surgery Study Completes Enrollment, Topline Data Expected Q1 18

    EyeGate (EYEG) reported Q3 financial results and provided a business update.  There continue to be no significant surprises in the financials.  Operating expenses continue to trend higher on progression of several development programs including EDP-437, which is in clinical trials for indications related to anterior uveitis and post-cataract surgery.

  • Capital Cube3 months ago

    ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EyeGate Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EYEG-US. Comparing the performance and risk of EyeGate Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Is Eyegate Pharmaceuticals Inc’s (EYEG) Liquidity As Good As Its Solvency?
    Simply Wall St.3 months ago

    Is Eyegate Pharmaceuticals Inc’s (EYEG) Liquidity As Good As Its Solvency?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Eyegate Pharmaceuticals Inc (NASDAQ:EYEG), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...

  • Capital Cube4 months ago

    ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EyeGate Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EYEG-US. Comparing the performance and risk of EyeGate Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to EyeGate Pharmaceuticals, Inc. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EyeGate Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EYEG-US. Comparing the performance and risk of EyeGate Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • EyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube6 months ago

    EyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis EyeGate Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of EyeGate Pharmaceuticals, Inc. – Sonoma Pharmaceuticals, Inc. and Daiichi Sankyo Company, Limited (SNOA-US and DSKYF-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • Zacks Small Cap Research6 months ago

    EYEG: Q2 Inline. Additional Trials Expected To Commence

    Q2 operating expenses were $3.5M, meaningfully lower than our $4.0M estimate - with all of the difference in R&D expense.  We think at least some of the difference relates to slower enrollment of the (EGP-437) Phase 3 uveitis study.  But, with additional activity expected in most of the ‘focused’ development programs, including EGP-437 in both uveitis and cataract surgery, and CMHA-S in the OBG indication, we think R&D expense will trend higher.